Episode 60: Riociguat in patients with PAH and Cardiometabolic Comorbidities
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Episode 60: Riociguat in patients with PAH and Cardiometabolic Comorbidities
-
Narrado por:
-
De:
Acerca de esta escucha
Returning for a second study this month, the JHLT Digital Media Editors conduct an internal discussion on the paper, “Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.”
The episode explores:
- The aging PAH population and the new comorbidities that must be considered in research
- How the study augments and expands on recent standards, like the 2022 ESC/ERS guidelines for pulmonary hypertension
- Limitations on the study and opportunities for future research
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you’re an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Those on lung transplant teams should check the previous episode for a study on how rewarming ischemia time affects lung transplant outcomes.
Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.